BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 31501384)

  • 1. [Preoperative Chemotherapy with DCF for Advanced Esophageal Cancer].
    Murata K; Kuroda D; Okamoto S; Fujinaka R; Arai K; Otowa Y; Mii Y; Kakinoki K; Mani M; Oka S
    Gan To Kagaku Ryoho; 2019 Aug; 46(8):1337-1339. PubMed ID: 31501384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Presence of Serum p53 Antibody Predicts the Pathological Tumor Response to Neoadjuvant Chemotherapy with Docetaxel, Cisplatin and Fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma.
    Hiyoshi Y; Yoshida N; Watanabe M; Kurashige J; Baba Y; Sakamoto Y; Baba H
    World J Surg; 2017 Feb; 41(2):480-486. PubMed ID: 27637603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neoadjuvant chemotherapy of triplet regimens of docetaxel/cisplatin/5-FU (DCF NAC) may improve patient prognosis of cStage II/III esophageal squamous cell carcinoma-propensity score analysis.
    Yamashita K; Katada N; Moriya H; Hosoda K; Mieno H; Katada C; Koizumi W; Hoshi K; Watanabe M
    Gen Thorac Cardiovasc Surg; 2016 Apr; 64(4):209-15. PubMed ID: 26868531
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic Advantage of Docetaxel/Cisplatin/ 5-Fluorouracil Neoadjuvant Chemotherapy in Clinical Stage II/III Esophageal Squamous Cell Carcinoma due to Excellent Control of Preoperative Disease and Postoperative Lymph Node Recurrence.
    Yamashita K; Hosoda K; Moriya H; Katada C; Sugawara M; Mieno H; Komori S; Katada N; Watanabe M
    Oncology; 2017; 92(4):221-228. PubMed ID: 28110330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation of operative outcomes of thoracoscopic esophagectomy after triplet chemotherapy with docetaxel, cisplatin, and 5-fluorouracil for advanced esophageal squamous cell carcinoma.
    Akiyama Y; Iwaya T; Endo F; Chiba T; Takahara T; Otsuka K; Nitta H; Koeda K; Mizuno M; Kimura Y; Sasaki A
    Surg Endosc; 2018 Jan; 32(1):391-399. PubMed ID: 28664431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant Chemotherapy with Divided-dose Docetaxel, Cisplatin and Fluorouracil for Patients with Squamous Cell Carcinoma of the Esophagus.
    Ojima T; Nakamori M; Nakamura M; Katsuda M; Hayata K; Kato T; Kitadani J; Tabata H; Takeuchi A; Iwahashi M; Yamaue H
    Anticancer Res; 2016 Feb; 36(2):829-34. PubMed ID: 26851048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of docetaxel, cisplatin, and 5-fluorouracil chemotherapy for superficial esophageal squamous cell carcinoma.
    Miyawaki Y; Nakajima Y; Kawada K; Okada T; Tokairin Y; Kawano T
    Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 27001629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of preoperative chemotherapy using docetaxel, cisplatin and fluorouracil with cisplatin and fluorouracil in patients with advanced carcinoma of the thoracic esophagus.
    Ui T; Fujii H; Hosoya Y; Nagase M; Mieno MN; Mori M; Zuiki T; Saito S; Kurashina K; Haruta H; Matsumoto S; Niki T; Lefor A; Yasuda Y
    Dis Esophagus; 2015; 28(2):180-7. PubMed ID: 24529073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prospective, multicenter phase I/II study of induction chemotherapy with docetaxel, cisplatin and fluorouracil (DCF) followed by chemoradiotherapy in patients with unresectable locally advanced esophageal carcinoma.
    Satake H; Tahara M; Mochizuki S; Kato K; Hara H; Yokota T; Kiyota N; Kii T; Chin K; Zenda S; Kojima T; Bando H; Yamazaki T; Iwasa S; Honma Y; Hamauchi S; Tsushima T; Ohtsu A
    Cancer Chemother Pharmacol; 2016 Jul; 78(1):91-9. PubMed ID: 27193097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Current status of neoadjuvant chemotherapy for advanced esophageal cancer].
    Tanabe S; Shirakawa Y; Maeda N; Katsube R; Ohara T; Sakurama K; Noma K; Fujiwara T
    Gan To Kagaku Ryoho; 2013 Nov; 40(12):1612-4. PubMed ID: 24393865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcomes of preoperative chemotherapy with docetaxel, cisplatin, and 5-fluorouracil followed by esophagectomy in patients with resectable node-positive esophageal cancer.
    Watanabe M; Baba Y; Yoshida N; Ishimoto T; Nagai Y; Iwatsuki M; Iwagami S; Baba H
    Ann Surg Oncol; 2014 Sep; 21(9):2838-44. PubMed ID: 24715216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Docetaxel plus 5-fluorouracil and cisplatin (DCF) induction chemotherapy for locally advanced borderline-resectable T4 esophageal cancer.
    Yokota T; Hatooka S; Ura T; Abe T; Takahari D; Shitara K; Nomura M; Kondo C; Mizota A; Yatabe Y; Shinoda M; Muro K
    Anticancer Res; 2011 Oct; 31(10):3535-41. PubMed ID: 21965775
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of esophagectomy after chemotherapy with biweekly docetaxel plus cisplatin and fluorouracil for advanced esophageal cancer: a retrospective cohort analysis.
    Akiyama Y; Sasaki A; Endo F; Nikai H; Amano S; Umemura A; Baba S; Chiba T; Kimura T; Takahara T; Nitta H; Otsuka K; Mizuno M; Kimura Y; Koeda K; Iwaya T
    World J Surg Oncol; 2018 Jul; 16(1):122. PubMed ID: 29966526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Pathological Complete Response in a Case of Advanced Esophageal Cancer with Widespread Lymph Node Metastases Treated Using Preoperative Chemotherapy with Docetaxel, Cisplatin, and 5-FU(DCF therapy)].
    Noro H; Hirao T; Takaichi S; Son C; Iwamoto K; Kono E; Yasumasa K; Mizuno H; Morimoto Y; Hatanaka N; Yamasaki Y
    Gan To Kagaku Ryoho; 2016 Nov; 43(12):2178-2180. PubMed ID: 28133261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of biweekly docetaxel, cisplatin, and 5-fluorouracil chemotherapy for advanced esophageal squamous cell carcinoma.
    Tanaka Y; Yoshida K; Yamada A; Tanahashi T; Okumura N; Matsuhashi N; Yamaguchi K; Miyazaki T
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1143-52. PubMed ID: 26896963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Long-Term Complete Response in Postoperative Multiple Lung and Mediastinal Lymph Node Metastases of Esophageal Cancer Using Systemic Chemotherapy with DCF Treatment - A Case Report].
    Katsumi C; Bamba T; Nakagawa S; Aizawa M; Matsuki A; Yabusaki H; Homma K
    Gan To Kagaku Ryoho; 2017 Jan; 44(1):75-78. PubMed ID: 28174385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Safety and Efficacy of Neoadjuvant Chemotherapy(UDON: 5-FU, Docetaxel, and Nedaplatin)for Esophageal Cancer].
    Konishi T; Komatsu S; Takeda R; Kanazawa H; Soga K; Shimomura K; Ikeda J; Taniguchi F; Shioaki Y
    Gan To Kagaku Ryoho; 2023 Dec; 50(13):1381-1383. PubMed ID: 38303281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Successful Treatment of Advanced Esophageal Cancer with DCF Chemotherapy and Pegfilgrastim].
    Gunjigake K; Okamoto K; Gabata R; Yamaguchi T; Ninomiya I; Fushida S; Ohta T
    Gan To Kagaku Ryoho; 2019 Jan; 46(1):61-63. PubMed ID: 30765644
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Three-arm phase III trial comparing cisplatin plus 5-FU (CF) versus docetaxel, cisplatin plus 5-FU (DCF) versus radiotherapy with CF (CF-RT) as preoperative therapy for locally advanced esophageal cancer (JCOG1109, NExT study).
    Nakamura K; Kato K; Igaki H; Ito Y; Mizusawa J; Ando N; Udagawa H; Tsubosa Y; Daiko H; Hironaka S; Fukuda H; Kitagawa Y;
    Jpn J Clin Oncol; 2013 Jul; 43(7):752-5. PubMed ID: 23625063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of initial induction chemotherapy with 5-fluorouracil, cisplatin, and docetaxel (DCF) for T4 esophageal cancer: a propensity score-matched analysis.
    Makino T; Yamasaki M; Miyazaki Y; Wada N; Takahashi T; Kurokawa Y; Nakajima K; Takiguchi S; Mori M; Doki Y
    Dis Esophagus; 2018 Apr; 31(4):. PubMed ID: 29190316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.